Antibacterial Drugs Market

Global Antibacterial Drugs Market Size, Share & Trends Analysis Report, By Drug Class (B-Lactams, Quinolones, Macrolides, Tetracycline, Aminoglycoside, Sulfonamide, and Phenicols), By Route of Administration (Enteral and Parenteral), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025745 | Category : Pharmaceuticals | Delivery Format: /

The global antibacterial drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Antibacterial drugs are the medicines that are used to detect and treat bacterial pathogens from the body with minimal to no toxic side effects on the body. The antibacterial drugs are also termed antibiotics, and they are widely used for the prevention as well as the treatment of infectious diseases all over the globe. The major factor for the growth of the market includes the increasing number of patients suffering from hygiene-related diseases in developing countries and developed countries. According to the National Center for Biotechnology (NCBI), bacterial/fungal diseases are responsible for the mortalities of more than 1.5 million people whereas it affects over a billion people every year. 

Further, the market is driven by the increasing immunity deficient population such as geriatrics, rise in exposure to infectious agents due to environmental factors such as pollution. However, the market is anticipated to be restrained by the high penetration of conventional drugs during the forecast period.

Some key players operating in the market include GlaxoSmithKline plc, Bayer AG, and Merck & Co., Inc., among others. These players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launches, and development in the existing product portfolio, and so on. For instance, in October 2019, GlaxoSmithKline plc announced that patient dosing has begun in a phase III clinical program investigating gepotidacin, the first in a new chemical class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors, in patients with uncomplicated urinary tract infection (uUTI, also known as acute cystitis) and urogenital gonorrhoea (GC).

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Drug Class

o By Route of Administration

Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape:  GlaxoSmithKline plc, Bayer AG, and Merck & Co., Inc., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Antibacterial Drugs Market Report by Segment

By Drug Class

    • B-Lactams

    • Quinolones

    • Macrolides

    • Tetracycline

    • Aminoglycoside

    • Sulfonamide

    • Phenicols

By Route of Administration

    • Enteral

    • Parenteral

Global Antibacterial Drugs Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa